

Figg, W. D., Dahut, W., Duray, P., Hamilton, M., Tompkins, A., Steinberg, S. M., ... & Reed, E. (2001). A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. *Clinical Cancer Research*, 7(7), 1888-1893.

Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. *New England Journal of Medicine*, 285(21), 1182-1186.

Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nature medicine*, 1(1), 27-30.

Folkman, J. (1995). Clinical applications of research on angiogenesis. *New England Journal of Medicine*, 333(26), 1757-1763.

Folkman, J., (2000) Tumour angiogenesis. In Bast RC, Kufe DW, Pollock RR, Weichselbaum RR, eds. *Cancer medicine*. 5th ed. Hamilton B.C. Decker Inc., pp. 132–152.

Folkman, J., Shing, Y. (1992). Angiogenesis. *Journal of Biological Chemistry*, 267(16), 10931-10934.

Fortunato, S. J., & Menon, R. (2002). Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. *Journal of assisted reproduction and genetics*, 19(10), 483-486.

Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004). Thalidomide. *The Lancet*, 363(9423), 1802-1811.

Frederick, L., Wang, X. Y., Eley, G., & James, C. D. (2000). Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. *Cancer research*, 60(5), 1383-1387.